|
|
Volumn 16, Issue 2, 2017, Pages 97-
|
|
Solanezumab: too late in mild Alzheimer's disease?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADUCANUMAB;
MONOCLONAL ANTIBODY;
PLACEBO;
SOLANEZUMAB;
ALZHEIMER DISEASE;
ALZHEIMER DISEASE ASSESSMENT SCALE;
AMYLOID PLAQUE;
COGNITION ASSESSMENT;
EDITORIAL;
HUMAN;
MINI MENTAL STATE EXAMINATION;
PRIORITY JOURNAL;
DRUG ADMINISTRATION;
PROCEDURES;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
TREATMENT OUTCOME;
ALZHEIMER DISEASE;
ANTIBODIES, MONOCLONAL, HUMANIZED;
DRUG ADMINISTRATION SCHEDULE;
HUMANS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
TREATMENT OUTCOME;
|
|
EID: 85009895674
PISSN: 14744422
EISSN: 14744465
Source Type: Journal
DOI: 10.1016/S1474-4422(16)30395-7 Document Type: Editorial |
|
Times cited : (51)
|
|
References (0)
|